# Repurposing Ivermectin for PKDL Treatment

> **NCT06251739** · EARLY_PHASE1 · COMPLETED · sponsor: **International Centre for Diarrhoeal Disease Research, Bangladesh** · enrollment: 30 (actual)

## Conditions studied

- Post-kala-azar Dermal Leishmaniasis

## Interventions

- **DRUG:** Ivermectin 6 Mg Oral Tablet
- **DRUG:** Miltefosine Oral Capsule

## Key facts

- **NCT ID:** NCT06251739
- **Lead sponsor:** International Centre for Diarrhoeal Disease Research, Bangladesh
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-30
- **Primary completion:** 2024-01-31
- **Final completion:** 2025-01-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06251739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06251739, "Repurposing Ivermectin for PKDL Treatment". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT06251739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*